STAT3 and hepatocellular carcinoma: Inhibition of STAT3 with sorafenib, the first-line recommended therapy for patients with advanced HCC, decreased CD133 levels and suppressed in vivo tumorigenicity by eradicating the liver tumor microenvironment (41).